These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7768640)

  • 1. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes.
    Zou Y; Ling YH; Reddy S; Priebe W; Perez-Soler R
    Int J Cancer; 1995 May; 61(5):666-71. PubMed ID: 7768640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
    Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
    Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.
    Zou Y; Priebe W; Ling YH; Perez-Soler R
    Cancer Chemother Pharmacol; 1993; 32(3):190-6. PubMed ID: 8500223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein.
    Wasan KM; Perez-Soler R
    J Pharm Sci; 1995 Sep; 84(9):1094-100. PubMed ID: 8537888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
    Zou Y; Priebe W; Stephens LC; Perez-Soler R
    Clin Cancer Res; 1995 Nov; 1(11):1369-74. PubMed ID: 9815933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
    Perez-Soler R; Ling YH; Zou Y; Priebe W
    Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.
    Wasan KM; Morton RE
    Pharm Res; 1996 Mar; 13(3):462-8. PubMed ID: 8692743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity.
    Perez-Soler R; Priebe W
    Cancer Res; 1990 Jul; 50(14):4260-6. PubMed ID: 2194651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
    Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
    Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size.
    Zou Y; Priebe W; Perez-Soler R
    Cancer Chemother Pharmacol; 1996; 39(1-2):103-8. PubMed ID: 8995506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of liposomal annamycin.
    Booser DJ; Perez-Soler R; Cossum P; Esparza-Guerra L; Wu QP; Zou Y; Priebe W; Hortobagyi GN
    Cancer Chemother Pharmacol; 2000; 46(5):427-32. PubMed ID: 11127949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifications in high-density lipoprotein lipid composition and structure alter the plasma distribution of free and liposomal annamycin.
    Wasan KM; Ng S; Cassidy SM
    J Pharm Sci; 1997 Jul; 86(7):872-5. PubMed ID: 9232531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
    Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
    Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
    Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
    Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.